Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 21 - Drugs for disorders of the muscular or neuromuscular system
Patents for A61P 21 - Drugs for disorders of the muscular or neuromuscular system (23,287)
04/2003
04/17/2003US20030073724 Central nervous system disorders
04/17/2003US20030073712 Antiinflamamtory agents; antiischemic agents
04/17/2003US20030073704 Analgesics; antidiabetic agents; antiinflamamtory agents
04/17/2003US20030073700 Central nervous system disorders; Parkinson's disease, Huntington's disease; psycological disorders
04/17/2003US20030073692 Anticancer agents; viricides; Alzheimer's diseases
04/17/2003US20030073669 N-heterocyclic derivatives as NOS inhibitors
04/17/2003US20030073123 Detection of modulators of gene transcription inhibition; obtain sample of cells, incubate with modulator, monitor transcription pattern, compare to control, evaluate for transcription inhibition
04/17/2003US20030072737 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
04/17/2003CA2463198A1 Pyrrolidinone derivatives
04/17/2003CA2462881A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process
04/17/2003CA2462862A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
04/17/2003CA2462806A1 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide
04/17/2003CA2461064A1 Inhibition of stat-1
04/17/2003CA2460625A1 Structural and cytoskeleton-associated proteins
04/17/2003CA2460476A1 Protein modification and maintenance molecules
04/17/2003CA2458388A1 Novel benzothiazine derivatives, their preparation and use
04/16/2003EP1302201A1 Pharmaceutical composition improved in peroral absorbability
04/16/2003EP1302115A1 Use of cystathionine
04/16/2003EP1301598A2 Cell cycle proteins and mitosis-associated molecules
04/16/2003EP1301535A2 G-protein coupled receptors
04/16/2003EP1301524A1 B7-like polynucleotides, polypeptides, and antibodies
04/16/2003EP1301514A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use
04/16/2003EP1301502A1 Novel compounds and their use as glycine transport inhibitors
04/16/2003EP1301201A1 Treatment of glycogen storage disease type ii
04/16/2003CN1411447A Polymorphic crystalline forms of celecoxib
04/16/2003CN1410082A Bone strengthening pill and its preparation method
04/16/2003CN1410059A Treating method and medicine kit containing somatotrophic hormone secretory agent
04/16/2003CN1105723C Spirocyclic metalloprotease inhibitors
04/15/2003US6548699 4,4*-(Isopropylidenedithio)-(2*,6*-di-tert-butylphenol)-(2,6-d i-tert-butylphenol-O*-acetic acid); antiarthritic, antiinflammatory agents; rheumatic and cardiovascular disorders
04/15/2003US6548522 N-substituted 2,2-diphenylacetamide or N-substituted 2-phenyl-2-pyridinylacetamide
04/15/2003US6548520 Substituted imidazoles having anti-cancer and cytokine inhibitory activity
04/15/2003US6548483 Nutritional preparation comprising ribose and medical use thereof
04/15/2003US6548279 For polypeptides able to catalyze the enzymatic function of superoxide dismutase, carbonic anhydrase, or HIV protease
04/10/2003WO2003029437A2 Secreted proteins
04/10/2003WO2003029293A2 Modulators of notch ic protease activity for use in immunotherapy
04/10/2003WO2003029276A2 Copolymers for suppression of autoimmune diseases, and methods of use
04/10/2003WO2003029268A1 Androstane 17-beta-carboxamides as androgen receptor modulators
04/10/2003WO2003029252A1 Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
04/10/2003WO2003029247A1 N-heterocyclyl hydrazides as neurotrophic agents
04/10/2003WO2003029200A2 Compounds useful as reversible inhibitors of cysteine proteases
04/10/2003WO2003028734A1 Triazepine derivatives as neurotrophic agents
04/10/2003WO2003028705A1 Pharmaceutical compositions comprising colloidal silicon dioxide
04/10/2003WO2003014326A3 Isolation and mobilization of stem cells expressing vegfr-1
04/10/2003WO2003004527A3 Novel neurotrophic factors
04/10/2003WO2003004493A8 Novel compounds, their preparation and use
04/10/2003WO2002096467A3 Pharmaceutical use for secreted bacterial effector proteins
04/10/2003WO2002092064A3 Therapeutic method for inducing tolerance
04/10/2003WO2002072826A3 Neurotrophic factors
04/10/2003WO2002059083A3 Novel compounds
04/10/2003WO2002008396A3 Human proteases
04/10/2003US20030069406 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of blood disorders
04/10/2003US20030069313 Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
04/10/2003US20030069292 Central nervous system disorders; anticonvulsants
04/10/2003US20030069287 Process for preparing prodrugs of benzenesulfonamide-containing cox-2 inhibitors
04/10/2003US20030069254 New arylsulfonyl derivatives with 5-HT6 receptor affinity
04/10/2003US20030069249 Analgesics; central nervous system disorders
04/10/2003US20030069210 Especially imidazolyl- or 1,2,4-triazolyl- pyrimidine derivatives
04/10/2003US20030069203 Method for increasing human performance by reducing muscle fatigue and recovery time through oral administration of adenosine triphosphate
04/10/2003US20030069192 May be administered along with Rutin, a Rutin congener and/or a Rutin derivative.
04/10/2003US20030069190 Alkali and alkaline earth metal salts of topiramate
04/10/2003CA2462795A1 Secreted proteins
04/10/2003CA2462643A1 Triazepine derivatives as neurotrophic agents
04/10/2003CA2462419A1 N-heterocyclyl hydrazides as neurotrophic agents
04/10/2003CA2459825A1 Compounds useful as reversible inhibitors of cysteine proteases
04/09/2003EP1300468A2 TRNA synthetase
04/09/2003EP1300396A1 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
04/09/2003EP1300148A2 Use of bismuth subgallate in inhibition of production of nitric oxide synthase
04/09/2003EP1299545A2 Drug metabolizing enzymes
04/09/2003EP1299538A2 Secreted proteins
04/09/2003EP1299412A2 Protein modification and maintenance molecules
04/09/2003EP1299385A2 Fused cyclic modulators of nuclear hormone receptor function
04/09/2003EP1299383A1 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders
04/09/2003EP1198453B1 N-(indolcarbonyl-)piperazin derivatives
04/09/2003EP0998494B1 Pompilid wasp-derived neuropeptides
04/09/2003EP0708768B1 Tri-substituted imidazoles having multiple therapeutic properties
04/09/2003CN1409639A TNF-alpha antagonist and LFA-1 antagonist for treating LFA-1 or TNF-alpha mediated disorder
04/09/2003CN1408442A Adsorbent for whole blood perfusion adsorbing therapy
04/09/2003CN1105115C 1'-[4-[1-(4-fluorophenyl)-1H-indole-3-yl]-1-butyl]- spiro [isobenzofuran-1(3H),4'-piperidine)] hydrohalogenides
04/09/2003CN1104901C Medicinal preparation containing lipophilicity inert gas
04/09/2003CN1104894C Pharmaceutical compositions containing hydroximic acid derivatives
04/08/2003US6544987 Compounds, compositions, and methods for stimulating neuronal growth and elongation
04/08/2003US6544759 Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosine
04/03/2003WO2003027263A2 Proteins associated with cell growth, differentiation, and death
04/03/2003WO2003027248A2 Antibody inhibitors of gdf-8 and uses thereof
04/03/2003WO2003027234A2 Small organic molecule regulators of cell proliferation
04/03/2003WO2003027228A2 Receptors and membrane-associated proteins
04/03/2003WO2003027115A1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
04/03/2003WO2003027075A2 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
04/03/2003WO2003026649A1 Methods of increasing endogenous testosterone levels
04/03/2003WO2003026638A1 Neuroprotective treatment methods using selective inos inhibitors
04/03/2003WO2003026579A2 Combination therapies for immune mediated diseases
04/03/2003WO2003026568A2 Androstanes as androgen receptor modulators
04/03/2003WO2003026566A2 Atlastin
04/03/2003WO2003026479A2 Methods of suppressing microglial activation
04/03/2003WO2002102313A3 Pyrimidine inhibitors of phosphodiesterase (pde) 7
04/03/2003WO2002092563A3 Protease inhibitors
04/03/2003WO2002070559A3 Nuclear hormone receptor ligand binding domains
04/03/2003WO2002024909A9 Receptor nucleic acids and polypeptides
04/03/2003WO2002010214A3 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
04/03/2003WO2002007743A3 Piper methysticum plant extract
1 ... 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 ... 233